CNBC 快讯 4月14日 13:23 BIIB专利悬崖 vs. 管线再平衡：生物技术股的二元分化格局 This biotech firm has room to run, even as its drug royalties are set to shrink Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will s… FG 100 读报告 →